In the R&D center of Guangdong JiAnTeBo Biotechnology Co, researchers are conducting experiments in the labs.

Since its establishment in Cuiheng New District over three years ago, this innovative pharmaceutical company has developed key pipelines for recombinant proteins, mRNA and small molecule compounds. Four of its products have been launched on the market, and several other products are soon to be launched.

JiAnTeBo was founded in December 2021. Currently, the company has more than 20 employees with doctoral and master's degrees, and over 60% of its employees are research personnel.

The company is engaging in developing drugs and functional foods around the new target of IL-27 against such diseases as obesity and insulin resistance.

According to Yin Zhinan, chairman, founder and chief scientist of JiAnTeBo, Ma'an Island in Cuiheng New District boasts a good environment for the development of biomedicine. The company is speeding up the commercialization of new research findings into market-oriented products, aiming to fill the gaps in related fields.